Twinbeech Capital LP Aurinia Pharmaceuticals Inc. Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $963,519 - $1.28 Million	-135,136 Reduced 92.98%	10,209 $91,000
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $1.13 Million - $1.78 Million	145,345 New	145,345 $1.13 Million
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $580,971 - $830,886	64,913 New	64,913 $652,000
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $377,287 - $843,921	-37,541 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $667,478 - $1.24 Million	37,541 New	37,541 $859,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.